Cubist Systematic Strategies, LLC Alzamend Neuro, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.49 - $0.77 $2,889 - $4,540	-5,897 Reduced 35.96%	10,503 $5,000
Q4 2022 Feb 14, 2023	BUY	$0.53 - $222.0 $8,692 - $3.64 Million	16,400 New	16,400 $9,000
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.2 $31,077 - $45,480	-37,900 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.91 - $2.23 $34,489 - $84,517	37,900 New	37,900 $47,000
Q4 2021 Feb 14, 2022	SELL	$1.9 - $3.08 $88,671 - $143,740	-46,669 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.28 - $7.68 $52,433 - $176,616	22,997 Added 97.15%	46,669 $144,000
Q2 2021 Aug 16, 2021	BUY	$8.12 - $13.5 $192,216 - $319,572	23,672 New	23,672 $207,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.